The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Alan Tan, MD, discusses factors influencing the choice of immunotherapy plus tyrosine kinase inhibitor vs dual IO in patients ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

The trials reported tumor shrinkage in 89% of TKI-naive and 56% of TKI-pretreated patients, with prolonged progression-free survival. Taletrectinib has a favorable safety profile and addresses unmet ...

The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

The safety profile aligned with other EGFR-targeting ... Limertinib is an orally-administrated, third-generation EGFR TKI with proprietary rights, approved by the China's NMPA for the treatment ...

During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants ...

Among TKI-resistant patients ... The molecule also had an excellent safety and tolerability profile, with maximum tolerated dose not having been reached. As the company noted, ELVN-001, at ...

Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial ...

Most treatment-emergent side effects were low grade and reversible, with a favorable safety profile. The study reported an 80% disease ... were treated with one prior tyrosine kinase inhibitor (TKI) ...